Coverage
-
September 16, 2021
A group of investors has urged a New Jersey federal judge to grant preliminary approval to a $1.6 million settlement with Galena Biopharma Inc. to resolve allegations the company caused a stock drop with purported misrepresentations regarding its fentanyl-based drug Abstral.
2 other articles on this case.
View all »